1.
Martin L, Alibhai S, Komisarenko M, Timilshina N, Finelli A. Identification of subgroups of metastatic castrate-resistant prostate cancer (mCRPC) patients treated with abiraterone plus prednisone at low- vs. high-risk of radiographic progression: An analysis of COU-AA-302. CUAJ [Internet]. 5Nov.2018 [cited 20Jun.2019];13(6). Available from: https://cuaj.ca/index.php/journal/article/view/5586